$0.430
-0.085 (-19.66%)終値時点
ESLA の同業比較
In the context of the broader market, ESLA competes directly with industry leaders such as QNTM and MRKR. With a market capitalization of $18.70M, it holds a significant position in the sector. When comparing efficiency, ESLA's gross margin of N/A stands against QNTM's N/A and MRKR's N/A. Such benchmarking helps identify whether Estrella Immunopharma Inc is trading at a premium or discount relative to its financial performance.
Estrella Immunopharma Inc の財務パフォーマンス
Estrella Immunopharma has reported consistent losses, with a net income of -2,302,339 USD in Q2 2026 and an EPS of -0.05. The company has a current ratio of 0.20, indicating liquidity issues.
Financials
FY2026Q2
YoY:
-62.41%
-2.08M
Operating Profit
FY2026Q2
YoY:
-58.41%
-2.31M
Net Income after Tax
FY2026Q2
YoY:
-66.67%
-0.05
EPS - Diluted
FY2024Q4
YoY:
+1972.07%
-896.07K
Free Cash Flow
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。